Sequenom, Inc. (SQNM) - NASDAQ
  • Nov. 12, 2012, 5:15 PM

    Sequenom (SQNM) says it's achieved positive results from a study of its RetnaGene AMD laboratory-developed test, which is designed to accurately predict the risk of disease progression of age-related macular degeneration. The announcement was made during its presentation today at the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago. Shares +0.3% AH.

    | Nov. 12, 2012, 5:15 PM
  • Nov. 12, 2012, 9:10 AM
    Premarket gainers: TIE +43%. JEF +24%. MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%.
    Losers: CLVS -41%. STSI -20%. NBG -11%.
    | Nov. 12, 2012, 9:10 AM
  • Nov. 9, 2012, 12:45 PM
    Midday top 10 gainers: HWG +66%. KIPS +41%. KYAK +27%. ZIP +25%. SQNM +22%. UBNT +19%. DGIT +17%. SQI +16%. CYTX +16%. ISIS +15%. Midday top 10 Losers: GRPN -27%. DTSI -26%. SCLN -24%. IDN -23%. RNDY -21%. III -17%. ADEP -17%. OSG -17%. STRA -16%. PTIX -15%.
    | Nov. 9, 2012, 12:45 PM
  • Nov. 8, 2012, 5:17 PM
    Sequenom (SQNM): Q3 EPS loss of $0.26 misses by $0.02. Revenue $22.9M misses by $280K. (PR)
    | Nov. 8, 2012, 5:17 PM
  • Nov. 8, 2012, 12:10 AM

    Notable earnings after Thursday’s close: AFFY, AGO, CBOU, CUBE, DAR, DGIT, DIS, DLB, DNN, EGLE, EVEP, GRPN, HALO, HOGS, IGT, IO, JAZZ, JWN, LGF, MCHP, MDRX, MKL, NVDA, PSA, RNDY, SD, SPRD, SQNM, UBNT, WPRT, WR, ZGNX, ZIP

    | Nov. 8, 2012, 12:10 AM
  • Nov. 7, 2012, 5:35 PM

    Notable earnings after Thursday’s close: AFFY, AGO, CBOU, CUBE, DAR, DGIT, DIS, DLB, DNN, EGLE, EVEP, GRPN, HALO, HOGS, IGT, IO, JAZZ, JWN, LGF, MCHP, MDRX, MKL, NVDA, PSA, RNDY, SD, SPRD, SQNM, UBNT, WPRT, WR, ZGNX, ZIP

    | Nov. 7, 2012, 5:35 PM
  • Sep. 17, 2012, 6:40 PM

    Sequenom (SQNM) says it's completed its private offering of $130M aggregate principal amount of 5% convertible senior notes due 2017. The company plans to use the proceeds to fund the commercialization of the MaterniT21 PLUS laboratory-developed test, as well as for other general corporate purposes.

    | Sep. 17, 2012, 6:40 PM | 1 Comment
  • Sep. 11, 2012, 9:10 AM
    Premarket gainers: WSB +91%. SNSS +48%. CTIC +15%. NOK +7%. CRTX +7%. RBS +6%. PSTI +5%.
    Losers: NAVB -31%. PPO -12%. PANW -8%. SQNM -7%. PPHM -6%.
    | Sep. 11, 2012, 9:10 AM
  • Sep. 10, 2012, 5:38 PM

    Sequenom (SQNM) announces a $100M private offering of convertible senior notes due 2017, with a 30-day option to purchase up to an additional $20M to cover over-allotments. The company plans to use the proceeds to fund the commercialization of its MaterniT21 PLUS laboratory-developed test, as well as for R&D, capital expenditures, working capital and general administrative expenses. Shares -7.5% AH.

    | Sep. 10, 2012, 5:38 PM
  • Aug. 28, 2012, 9:16 AM

    Sequenom (SQNM) +3.9% premarket on news its subsidiary has completed several international distribution agreements that will expand access to the MaterniT21 PLUS testing service outside the U.S. MaterniT21 PLUS is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks gestation.

    | Aug. 28, 2012, 9:16 AM
  • Aug. 16, 2012, 9:10 AM
    Premarket gainers: BTH +23%. VQ +17%. EA +10%. SINA +8%. CSTR +8%. OCZ +8%. CSCO +7%. SQNM +6%. PETM +6%.
    Losers: IDIX -39%. MCP -8%. NTES -8%. A -7%. DLTR -6%.
    | Aug. 16, 2012, 9:10 AM | 1 Comment
  • Aug. 3, 2012, 9:15 AM
    Premarket gainers: OPEN +19%. MELI +17%. SKUL +13%. LNKD +11%. ATPG +11%. VHC +10%. KOG +10%. KCG +10%. STEM +8%. SQNM +8%. DB +7%. ING +7%. WFR +7%. E +6%. SI +5%. MT +5%. ATAX +5%. BCS +5%.
    Losers: ZIP -35%. HNT -24%. BODY -18%. MCP -15%. XIDE -13%. REE -8%. GLUU -7%. ONNN -7%.
    | Aug. 3, 2012, 9:15 AM
  • Jul. 26, 2012, 6:27 PM
    Sequenom (SQNM): Q2 EPS of -$0.26 misses by $0.05. Revenue of $18.3M (+37.6% Y/Y) misses by $0.89M. Shares -3.8% AH. (PR)
    | Jul. 26, 2012, 6:27 PM
  • Jul. 6, 2012, 12:09 PM

    Sequenom (SQNM -4.2%) sinks after a California District Court denied its petition for an injunction against Ariosa Diagnostics to prevent the company from offering or selling its Harmony Prenatal Test, pending resolution of current litigation between the two companies.

    | Jul. 6, 2012, 12:09 PM
  • Jul. 6, 2012, 9:10 AM
    Premarket gainers: BOOT +81%. PCX +10%. JRCC +6%.
    Losers: INFA -30%. ALXA -11%. APKT -10%. AONE -8%. SQNM -6%.
    | Jul. 6, 2012, 9:10 AM
  • May 17, 2012, 5:24 PM

    Sequenom (SQNM) says the recently announced provider network participation agreement with Coventry Health Care (CVH) has been terminated without cause by Coventry. The agreement was intended to provide members in the network with coverage for Sequenom CMM's MaterniT21 PLUS laboratory-developed test. SQNM -7.8% AH.

    | May 17, 2012, 5:24 PM
Company Description
Sequenom, Inc. provides early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in 1994 and is headquartered in San Diego, CA.
Sector: Healthcare
Industry: Biotechnology
Country: United States